132 related articles for article (PubMed ID: 23698198)
21. [Therapeutic drug monitoring of methotrexate after its administration in high-dose protocols].
Le Guellec C; Blasco H; Benz I; Hulin A;
Therapie; 2010; 65(3):163-9. PubMed ID: 20699066
[TBL] [Abstract][Full Text] [Related]
22. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs.
de Miguel D; García-Suárez J; Martín Y; Gil-Fernández JJ; Burgaleta C
Nephrol Dial Transplant; 2008 Dec; 23(12):3762-6. PubMed ID: 18779628
[No Abstract] [Full Text] [Related]
23. [Managing methotrexate toxicity: a case report].
Fernández Megía MJ; Alós Almiñana M; Terol Castera MJ
Farm Hosp; 2004; 28(5):371-4. PubMed ID: 15504095
[TBL] [Abstract][Full Text] [Related]
24. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis.
May J; Carson KR; Butler S; Liu W; Bartlett NL; Wagner-Johnston ND
Leuk Lymphoma; 2014 Jun; 55(6):1345-9. PubMed ID: 24004183
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
Fukuhara K; Ikawa K; Morikawa N; Kumagai K
J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
[TBL] [Abstract][Full Text] [Related]
26. Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis.
Wang X; Song Y; Wang J; He J; Liu R; Li X; Huang H; Zhang J
Int J Clin Pharm; 2020 Feb; 42(1):23-30. PubMed ID: 31916121
[TBL] [Abstract][Full Text] [Related]
27. Prolonged accumulation of high-dose methotrexate in a case with large liver cysts.
Kawakami M; Omori H; Yamagami T; Soma T
Cancer Chemother Pharmacol; 2009 Aug; 64(3):619-22. PubMed ID: 19319534
[TBL] [Abstract][Full Text] [Related]
28. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
29. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
30. [The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate].
Blasco H; Silly S; Tournamille JF; Gyan E; Sénécal D; André V; Colombat P; Le Guellec C
Therapie; 2008; 63(1):19-28. PubMed ID: 18387272
[TBL] [Abstract][Full Text] [Related]
31. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors.
Santucci R; Levêque D; Lescoute A; Kemmel V; Herbrecht R
Anticancer Res; 2010 Sep; 30(9):3807-10. PubMed ID: 20944174
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
33. [A Survey of the Adverse Effects and Influence of Concomitant Drugs for Methotrexate Intrathecal Administration].
Uchiyama M; Ueno M; Takamatsu Y; Matsuo K; Imakyure O; Kamimura H
Yakugaku Zasshi; 2018; 138(1):111-115. PubMed ID: 29311456
[TBL] [Abstract][Full Text] [Related]
34. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia.
Diaz J; Thomas MB; Paz-Pabon C; Hernandez E
J Reprod Med; 2012; 57(9-10):411-4. PubMed ID: 23091988
[TBL] [Abstract][Full Text] [Related]
37. Intravenous radiographic contrast administered prior to high-dose methotrexate and subsequent toxicity requiring the use of glucarpidase.
Schultz TE; Lynch AC
J Oncol Pharm Pract; 2019 Jun; 25(4):993-997. PubMed ID: 29651915
[TBL] [Abstract][Full Text] [Related]
38. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
[TBL] [Abstract][Full Text] [Related]
39. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
[TBL] [Abstract][Full Text] [Related]
40. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
